Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab First-Line Monotherapy in PD-L1 ≥50% Advanced NSCLC
ChiCTR2600127826Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600127826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127826.